Atrial fibrillation (AF) is the most common cardiac arrhythmia. Many medical conditions, including hypertension, diabetes, obesity, sleep apnea, and heart failure, increase the risk for AF. Cardiomyocytes have unique metabolic characteristics to maintain adenosine triphosphate production. Significant changes occur in myocardial metabolism in AF. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been used to control blood glucose fluctuations and weight in the treatment of type 2 diabetes and obesity. GLP-1RAs have also been shown to reduce oxidative stress, inflammation, autonomic nervous system modulation, and mitochondrial function. This article reviews the changes in metabolic characteristics in cardiomyocytes in AF. Although the clinical trial outcomes are unsatisfactory, the findings demonstrate that GLP-1 RAs can improve myocardial metabolism in the presence of various risk factors, lowering the incidence of AF.

心房颤动（AF）是最常见的心律失常。许多疾病，包括高血压、糖尿病、肥胖、睡眠呼吸暂停和心力衰竭，都会增加房颤的风险。心肌细胞具有独特的代谢特征来维持三磷酸腺苷的产生。AF 时心肌代谢发生显着变化。胰高血糖素样肽-1 受体激动剂 (GLP-1RA) 已被用于控制 2 型糖尿病和肥胖症治疗中的血糖波动和体重。GLP-1RA 还被证明可以减少氧化应激、炎症、自主神经系统调节和线粒体功能。本文就房颤时心肌细胞代谢特征的变化进行综述。尽管临床试验结果并不令人满意，但研究结果表明，GLP-1 RAs可以在存在各种危险因素的情况下改善心肌代谢，降低房颤的发生率。